Key result
Tacrine reduced the incidence of ischaemia-induced ventricular fibrillation from 70% to 0% at 10.0 microM (p<0.05) and widened the QT interval in isolated rat hearts.
Why the study?
Does tacrine reduce the incidence of ventricular fibrillation in isolated rat hearts subjected to ischaemia and reperfusion?
Does tacrine reduce the incidence of ventricular fibrillation in isolated rat hearts subjected to ischaemia and reperfusion?
Absolute Event Rate: 0% vs 70%
p-value: p=<0.05
Tacrine demonstrates antiarrhythmic properties in a rat model of ischaemia-reperfusion by reducing ventricular fibrillation, an effect associated with QT widening and sinus bradycardia.
Suggests antiarrhythmic potential in ischemia-reperfusion models; leaves open translation to human ventricular arrhythmia prevention.
OBJECTIVE: Tacrine was used as a tool to examine whether block of inward rectifying potassium current (IK1) represents a mechanism for suppression of arrhythmias induced by ischaemia and reperfusion. METHODS: Isolated rat hearts (n = 10-12 per group) were subjected to 30 min left regional ischaemia followed by reperfusion with and without tacrine. Rat heart was used to permit delayed rectifier (IK) block to be disregarded in interpretation of results (rat ventricle is deficient in functional IK). RESULTS: The incidence of ischaemia-induced ventricular fibrillation was reduced from 70% to 42%, 17% (p < 0.05), and 0% (p < 0.05) in hearts perfused with 0, 0.1, 1.0, and 10.0 microM tacrine. Likewise, the incidence of reperfusion induced ventricular fibrillation was reduced from 100% to 90%, 75%, and 50% (p < 0.05), respectively. Indirect evidence of repolarisation delay by tacrine was provided by QT widening; for example, 15 min after the onset of ischaemia, QT (at 100% repolarisation) was increased from 194(SEM 6) to 231(17), 235(13) (p < 0.05), and 341(24) ms (p < 0.05) by increasing concentrations of drug. QT interval measured in individual hearts during ischaemia correlated inversely with arrhythmia score (r2 = 0.392; p < 0.001). Tacrine had no effect on RR interval, coronary flow, recovery of flow during reperfusion, or occluded zone size. Tacrine caused bradycardia (significant at the 1.0 and 10.0 microM concentrations). In additional hearts (n = 12 per group), reversal of 10.0 microM tacrine-induced sinus bradycardia by left atrial pacing (5 Hz) significantly reduced tacrine induced QT widening (p < 0.05), and increased the incidence of ventricular fibrillation from 0% to 42% (although significant antiarrhythmic and QT widening effects were still present); 10.0 microM tacrine failed to reduce the incidence of reperfusion induced ventricular fibrillation in paced hearts (92% incidence v 100% in controls). CONCLUSIONS: The novel antiarrhythmic effects of tacrine, a drug with established blocking action on IK, IK1, and slow inward current, appear to result from QT widening in the rat (dependent partly on IK1 blockade in the ventricles and partly on drug induced sinus bradycardia).
No takes yet. Share an insight, caveat, or question.
Rees et al. (1993) studied Ischaemia and reperfusion induced arrhythmias. Tacrine vs. Control (0 microM tacrine) was evaluated on Incidence of ischaemia-induced ventricular fibrillation (p=<0.05). Tacrine reduced the incidence of ischaemia-induced ventricular fibrillation from 70% to 0% at 10.0 microM (p<0.05) and widened the QT interval in isolated rat hearts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: